Scarica l'app Stockscreener
42.72
3.43%
1.478
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$41.24
Aprire:
$41.31
Volume 24 ore:
241.43K
Relative Volume:
0.33
Capitalizzazione di mercato:
$2.40B
Reddito:
$651.97M
Utile/perdita netta:
$59.71M
Rapporto P/E:
39.94
EPS:
1.0696
Flusso di cassa netto:
$172.03M
1 W Prestazione:
+0.51%
1M Prestazione:
+28.79%
6M Prestazione:
+7.91%
1 anno Prestazione:
+26.76%
Intervallo 1D:
$41.01
$42.84
Intervallo di 1 settimana:
$40.26
$42.84
Portata 52W:
$29.16
$43.62
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
42.80 | 2.27B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
151.93 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.695 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.92 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Short Term Trend Reversal in Supernus Pharmaceuticals Inc. Possible [Portfolio Gains Report]Free Daily Stock Momentum Reports - 선데이타임즈
Statutory Profit Doesn't Reflect How Good Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are - Yahoo Finance
5 Insightful Analyst Questions From Supernus Pharmaceuticals’s Q2 Earnings Call - ca.finance.yahoo.com
Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN) - MSN
Supernus Pharmaceuticals shares rise 1.48% intraday after Lotus Pharmaceuticals reported a 6% revenue increase in the first half of 2025. - AInvest
Supernus Announces Second Quarter 2025 Financial Results - ADVFN Brasil
RSI + MACD Show Convergence for Supernus Pharmaceuticals Inc.High Conviction Intraday Stock Signals Detected - metal.it
CEO’s Major Stock Sale Shakes Up Supernus Pharmaceuticals - TipRanks
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2025 Earnings Call Transcript - Insider Monkey
Supernus Pharmaceuticals Shares Dip Amid Growth Plans - TipRanks
Supernus Pharmaceuticals’ Earnings Call Highlights Growth Amid Challenges - TipRanks
SUPN Stock Surge: What’s Driving It? - StocksToTrade
Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today - Yahoo Finance
Supernus Pharmaceuticals price target raised to $43 from $38 at Stifel - Investing.com Canada
Supernus Pharmaceuticals (SUPN) Price Target Raised by Cantor Fi - GuruFocus
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD - Investing.com
Supernus Pharmaceuticals stock hits 52-week high at 40.3 USD By Investing.com - Investing.com Australia
Supernus 2025 Q2 Earnings Mixed Results as Net Income Grows 13% - AInvest
Supernus Pharmaceuticals Q2 CY2025 Financial Results: Exceeding Market ExpectationsNews and Statistics - IndexBox
Supernus: Q2 Earnings Snapshot - New Haven Register
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q2 2025 Earnings Call Highlights: Innovation and Strategic ... By GuruFocus - Investing.com Canada
Supernus Pharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Supernus Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Supernus (SUPN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Supernus Pharmaceuticals Delivers Growth With Qelbree And GOCOVRI - Finimize
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
Supernus Pharmaceuticals Q2 2025: Navigating Contradictions in ONAPGO, Qelbree, and ZURZUVAE Growth - AInvest
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales - TradingView
Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses By Investing.com - Investing.com South Africa
Earnings call transcript: Supernus Q2 2025 revenue beats forecast, EPS misses - Investing.com
Supernus Pharmaceuticals Q2 revenue falls - MarketScreener
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SUPERNUS PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Supernus Pharmaceuticals Announces Q2 2025 Financial Results and Acquisition of Sage Therapeutics - Quiver Quantitative
Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings Report PreviewNews and Statistics - IndexBox
Supernus Pharmaceuticals (SUPN) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
When is Supernus Pharmaceuticals Inc. stock expected to show significant growthExceptional growth trajectory - Jammu Links News
What makes Supernus Pharmaceuticals Inc. stock price move sharplyAchieve superior returns through strategic trading - Jammu Links News
Is Supernus Pharmaceuticals Inc. a growth stock or a value stockFree Investment Timing Strategies - Jammu Links News
What are the technical indicators suggesting about Supernus Pharmaceuticals Inc.Rapid market gains - Jammu Links News
Why is Supernus Pharmaceuticals Inc. stock attracting strong analyst attentionUnlock daily market insights for better trades - Jammu Links News
Should I hold or sell Supernus Pharmaceuticals Inc. stock in 2025Build wealth steadily with proven methods - Jammu Links News
What are analysts’ price targets for Supernus Pharmaceuticals Inc. in the next 12 monthsStay ahead with daily expert stock picks - Jammu Links News
Is Supernus Pharmaceuticals Inc. a good long term investmentSuperior portfolio returns - Jammu Links News
Supernus Acquires Sage Therapeutics to Strengthen Neuropsychiatric Portfolio - AInvest
Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics - Yahoo Finance
SAGE Therapeutics Announces Nasdaq Delisting Following Merger and Board Changes - AInvest
What institutional investors are buying Supernus Pharmaceuticals Inc. stockTop Growth Ideas For 2025 - Jammu Links News
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Supernus Pharmaceuticals Inc Azioni (SUPN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Khattar Jack A. | President, CEO |
Aug 06 '25 |
Sale |
42.02 |
140,000 |
5,883,360 |
1,030,183 |
3.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):